• Users Online: 797
  • Print this page
  • Email this page
ARTICLE
Year : 2004  |  Volume : 9  |  Issue : 2  |  Page : 72-76

Therapeutic benefits of maximum androgen blockade and tolerability of bicalutamide in patients with advanced prostate cancer


1 Department of Surgery, University of Nigeria Teaching Hospital, Enugu, Nigeria
2 Medical Department, AstraZeneca, P. O. Box 3560, Ikeja, Lagos, Nigeria
3 Department of Surgery, Lagos University Teaching Hospital, Lagos, Nigeria
4 Department of Surgery, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria

Correspondence Address:
A E Aghaji
Urology Unit, Department of Surgery, University of Nigeria Teaching Hospital, Enugu
Nigeria
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Aim: To assess the therapeutic benefits of Maximum Androgen Blockade and the Tolerability of Bicalutamide, an oral non-steroidal anti-androgen in patients with advanced prostate cancer. Patients and Methods: A total of forty-nine(49) male patients aged between 42 and 84 years with tumour grades T2, T3 and T4 were enrolled in a multi-centre clinical trial to receive bicatutamide 50mg daily following surgical castration. Patients were assessed for disease status, adverse events and quality of life. Results: Thirty-three (33) patients completed the study and had therapy for 48 weeks, 90.9% of whom had complete response while the quality of life due to urinary symptoms was also markedly improved. The profile of adverse events was mild. Conclusion: Bicalutamide given as a daily dose of 50mg in combination with surgical castration is a well tolerated therapy and has therapeutic benefits in African patients with advanced prostate cancer.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed33    
    Printed0    
    Emailed0    
    PDF Downloaded4    
    Comments [Add]    

Recommend this journal